Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, United States.
Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, United States.
Resuscitation. 2020 Feb 1;147:53-56. doi: 10.1016/j.resuscitation.2019.12.014. Epub 2019 Dec 28.
We sought to determine the outcomes of patients with an Impella CP percutaneous mechanical circulatory support (MCS) device deployed during a cardiac arrest.
The Impella CP device is indicated for left ventricular support in patients with cardiogenic shock. The utility of percutaneous MCS in the setting of cardiac arrest during cardiopulmonary resuscitation (CPR) remains unclear.
We retrospectively examined data from patients supported with an Impella CP device for cardiogenic shock complicated by cardiac arrest between April 2015 and April 2017 at a single academic medical center. Patients with cardiac arrest who underwent Impella CP placement during CPR were compared to those who had return of spontaneous circulation (ROSC) prior to Impella CP placement.
We identified 22 patients with cardiogenic shock complicated by cardiac arrest (average age 64 years, 23% female) who underwent placement of an Impella CP device. The majority of patients (68%) underwent support for cardiogenic shock secondary to an acute myocardial infarction. Seven of the 22 patients (32%) underwent Impella CP placement during CPR and 15 (68%) underwent Impella CP insertion following ROSC. The in-hospital mortality was 86% in the group of patients who had the Impella CP placed during CPR and 56% in the group with ROSC prior to Impella CP insertion, (p = 0.19).
Based on our single center retrospective analysis, the mortality rate of patients undergoing placement of an Impella CP during CPR is 86%. Further study is necessary to better understand the utility of the Impella CP mechanical circulatory support device during a cardiac arrest.
我们旨在确定在心脏骤停期间使用 Impella CP 经皮机械循环支持(MCS)设备的患者的预后。
Impella CP 设备适用于因心源性休克而出现左心室支持的患者。在心肺复苏(CPR)期间心脏骤停时经皮 MCS 的应用仍然不清楚。
我们回顾性地研究了 2015 年 4 月至 2017 年 4 月期间在一个学术医疗中心因心源性休克合并心脏骤停接受 Impella CP 治疗的患者的数据。将在 CPR 期间接受 Impella CP 放置的心脏骤停患者与在 Impella CP 放置前恢复自主循环(ROSC)的患者进行比较。
我们确定了 22 例因心源性休克合并心脏骤停(平均年龄 64 岁,23%为女性)接受 Impella CP 设备放置的患者。大多数患者(68%)因急性心肌梗死导致心源性休克接受支持治疗。22 例患者中有 7 例(32%)在 CPR 期间接受了 Impella CP 放置,15 例(68%)在 ROSC 之前接受了 Impella CP 插入。在 CPR 期间放置 Impella CP 的患者组的院内死亡率为 86%,在 ROSC 之前放置 Impella CP 的患者组的死亡率为 56%(p=0.19)。
基于我们的单中心回顾性分析,在 CPR 期间进行 Impella CP 放置的患者死亡率为 86%。需要进一步的研究来更好地了解 Impella CP 机械循环支持设备在心脏骤停期间的应用。